In deliveryUnited Kingdom
CDMO for EMBED 3.0 Research Study
- Published
- Published 27 April 2026
Overview
Cardiff University awarded a contract worth USD 325,000 to ProMed Pharma, LLC on 26 April 2026 for Contract Development and Manufacturing Organization (CDMO) services for the EMBED 3.0 research study. The scope involves manufacturing of microinjection-moulded formulations containing active pharmaceutical ingredients, which was separated from clinical trial services to meet the program's specialized technical requirements.
Key details
- Country
- United Kingdom
- Status
- In delivery
- Procedure
- Direct
- Published
- 27 April 2026
Award outcome
- Awarded value
- US$325,000
- Award date
- 26 April 2026
- Contract period
- 10 May 2026 → 31 December 2026
- ProMed Pharma, LLC
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract
27 April 2026
View notice ↗Contract
27 April 2026
View notice ↗
Contracting authority
Cardiff University
BuyerCardiff, United Kingdom
GB-PPON: PHVT-4343-HWYR
Authority website ↗
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.